•idea07:00
Menopause: 6,000 new customers a day and almost nobody building
Steph presents menopause as the clearest overlooked opportunity in the aging stack. Below 55, cardiovascular illness is a more likely cause of mortality in men; after 55, around the menopause stage, that reverses, because menopause functions as a hugely accelerated aging period for women. Roughly 6,000 US women hit menopause every single day and encounter what is commonly described as the 34 symptoms. She contrasts this with fertility, where Flo, essentially a simplistic period tracker, claims over 380 million users. Early entrants include Bonafide and Genev. Her explanation for the gap is structural: there are fewer female entrepreneurs and very few founders over 50, so nobody in the building cohort has lived the problem.
- Cardiovascular mortality risk flips from men to women around 55
- Roughly 6,000 US women enter menopause every day
- Commonly cited as 34 distinct symptoms
- Flo, a simple period tracker, reports over 380 million users
- Bonafide and Genev are early entrants in a near-empty category
“one really interesting one is menopause so menopause is when women's ovaries stop working”
“people often refer to th 34 symptoms of menopause”
“at least even publicly on their site they say over 380 million people use it”
#menopause#healthcare startups#overlooked markets
•idea15:30
Assisted living economics and the missing premium tier
Steph reads a Numlock paragraph on assisted living: from 2004 to 2021 the median annual price rose 31% faster than inflation to $54,000 per year, there are 31,000 US facilities, four out of five run for profit, half of operators clear annual returns of 20% or more above operating cost, and 850,000 older Americans live in them. Sam questions whether the sector is valued as real estate, like hotels, in which case 20% is excellent, or as an operating business, where it would be unremarkable. He concludes he would happily invest in a nursing home fund but would not want to operate one. Steph, with aging parents, argues the real gap is quality: most options are ones you do not feel good about using, and she sees room for a premium tier where families feel genuinely good about the placement even at five times the price, given some families already pay $20,000 to $30,000 a month.
- Median assisted living cost is $54,000 per year, rising 31% faster than inflation since 2004
- 31,000 US facilities, four in five for-profit, half clearing 20%+ returns
- 850,000 older Americans currently live in assisted living
- Valuation likely resembles real estate rather than an operating business
- The premium tier families feel good about is largely missing
“there are 31,000 assisted living facilities in the United States four out of every five are run as for-profits”
“I would love to invest in a nursing home fund but I would not want to operate a nursing home”
“imagine the the premium version of Assisted Living where you feel really really good about sending your grandparent your mom your sister whatever it is…”
#assisted living#real estate#unit economics
•idea22:00
Assisted living reimagined as a revival facility
Steph proposes merging the new-age fitness and longevity trend with the assisted living industry. Instead of a place you go to die, the facility becomes somewhere you go for a revival: you arrive at 80 with a VO2 max of 15 and leave with it at 25. She grounds this in Peter Attia's examples of people in their 80s, 90s and past 100 who had not previously taken care of themselves and completely reshaped their fitness after starting a regimen. Sam agrees in principle but is sceptical about American adoption outside coastal cities, contrasting Austin's saturated fitness culture with the Midwest, and telling a story about a family member hospitalised with diabetes whose overweight doctor offered only 'eat healthy' as guidance. He counters with evidence that fitness is a keystone behaviour: European and Asian prisons mandating an exercise hour, and a friend whose nonprofit taught homeless men to run on the theory that caring about your body leads to caring about everything else.
- Reframe the facility from end-of-life storage to physical revival
- Illustrative target: VO2 max from 15 to 25 at age 80
- Attia documents late-start transformations past 100
- Sam doubts adoption outside coastal fitness cultures
- Fitness as a keystone habit: prison exercise hours, teaching homeless men to run
“what if you go there for like a Revival um what if you go there with a V2 Max of 15 and all of a…”
“if you learn how to get up at 5:00 a.m. and care about Fitness you're likely to care about other things”
#assisted living#longevity#fitness culture
•idea28:30
Over-the-counter CGMs and the case for a Strava for glucose
Steph flags that Dexcom, holding roughly 40% CGM market share, launched Stelo at the end of August, the first over-the-counter FDA-approved continuous glucose monitor. Previously a prescription was effectively required, so few people sought one out. She has worn one for two weeks and loves it, because unlike her Eight Sleep, Apple Watch and her husband's several Oura rings, the readout is granular enough to act on. Sam, an investor in Levels, notes CGMs are harsh in the same way DEXA scans are: you eat what you consider a whole food and the monitor alarms. Steph's business idea is a Strava for CGMs, using Dexcom's semi-open API, where users socialise and compete on time in range, spike size and the dawn effect. The existing proof of appetite is the Glucose Goddess, with 5 million Instagram followers, 1 million on YouTube, a $5-a-month recipe club, and a new supplement called Anti-Spike whose separate site already does over 100,000 views a month.
- Dexcom's Stelo is the first over-the-counter FDA-approved CGM, launched end of August
- Dexcom holds roughly 40% CGM market share and has a semi-open API
- CGMs are granular where sleep and ring wearables are too broad to act on
- Proposed product: a Strava for CGMs competing on time in range and spike size
- Glucose Goddess has 5M Instagram followers and a product site doing 100k+ monthly views
“their new product Stell is the first over-the-counter FDA approved CGM”
“I think there should be a Strava for cgms”
“she's got 5 million followers on Instagram 1 million on YouTube”
#cgm#quantified self#consumer health
•idea35:30
The CGM loss leader, and a $900 deposit challenge that worked
Steph pitches a marketing play: a Stelo costs around $50 for two weeks, cheap enough to give away free on the condition that the user wears it for two weeks and logs what they eat and how they live. At the end you hold an unusually rich picture of that person's metabolic health, diet and exercise, which supports a stack of follow-on offers, a health concierge subscription, a nutrition or exercise educator, a personal trainer, referral deals with local gyms, and a resale arrangement with Dexcom for their next CGM. Sam supplies a real precedent: his friend Justin Mares ran wearablechallenge.com during Covid. Sam Venmoed $900, then had to send daily proof that his blood glucose stayed below roughly 120, earning $30 back per compliant day, with a full refund at 100% success. He failed about four times, always on things he assumed were safe like a particular fruit or a raspberry-flavoured dressing. He calls it brilliant and says Justin reported it was fairly successful, though it was later shut down.
- Stelo costs about $50 for two weeks, cheap enough to use as a loss leader
- Two weeks of logged data becomes the asset that sells concierge, coaching and gym referrals
- A Dexcom resale arrangement covers repeat CGM purchases
- Precedent: wearablechallenge.com, a $900 deposit refunded at $30 per compliant day
- Sam failed roughly four times, always on foods he assumed were safe
“you could imagine a business where you you'd have to M like get this really right but um you give them the Stell for free”
“I venmoed him $900”
“I got $30 back and so by the end of the challenge if I would had a 100% success rate I got my whole $900…”
#business model#cgm#accountability